NCT00003693View on ClinicalTrials.gov

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 18, 1998

Primary Completion Date

October 30, 2001

Study Completion Date

October 30, 2001

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Dolastatin 10

IV bolus once every 3 weeks.

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003693 - Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter